医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Study Demonstrates Decreased Incidence of Groin Surgical Site Infection with Prevena™ Incision Management System

2013年01月23日 AM02:25
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Kinetic Concepts, Inc. confirmed today that, in a study published in the Journal of Vascular Surgery1, the Prevena Incision Management System significantly decreased the incidence of groin surgical site infections (SSIs) in patients after vascular surgery.

Groin wound infection is a significant cause of post-operative complications in vascular surgery patients. Studies have reported that SSIs of the groin can increase hospital stay by more than 9 days, costing facilities more than $20,000 per infection to treat and can have an adverse impact on patient quality of life1. Prevena Therapy has demonstrated the potential to significantly reduce these costs.

“Vascular surgeries are going up, not down,” said Tim Matatov, MD, an author of the Louisiana State University study. “This study showed that by using Prevena Therapy we were able to reduce associated infections in patients at risk for post-operative complications such as infection.”

In this retrospective study, 90 patients undergoing vascular procedures were divided into a “Prevena group” (41 patients, 52 incisions) and a “non-Prevena group” (49 patients, 63 incision). Incisions in the non-Prevena group were managed using either an absorbent dressing or skin adhesive. Results demonstrated a statistically significant (p-value=0.0011) lower incidence of overall infection for patients treated with Prevena Therapy. In the non-Prevena treated group, 19/63 (30%) of incisions developed groin wound infections, whereas 3/52 (6%) patients in the Prevena group developed groin wound infections.

“These results underscore a significant clinical and economic benefit of the Prevena System for patients considered at risk for developing a groin SSI,” said Ron Silverman, MD, chief medical officer, KCI. “This is good news for physicians looking for an effective treatment option for their patients and for hospitals wanting to reduce SSI-related costs.”

This is yet another recent addition to the growing body of evidence supporting the role of Prevena System in the management of closed incisions. Prevena Therapy represents continuing efforts by KCI to change the practice of medicine with evidence-based solutions that help speed healing, reduce complications and improve the lives of patients.

The Prevena Incision Management System is indicated to manage closed incisions that continue to drain following sutured or stapled closure. For more information about KCI, please visit www.KCI1.com.

About KCI

Kinetic Concepts, Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 25 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively impacting patient care by developing customer-driven innovation to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at www.KCI1.com.

1Matatov T, Reddy KN, Doucet LD, Zhao CX, Zhang WW. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg 2013 January 9.

CONTACT

KCI Corporate Communications
Mike Barger, 210-255-6824
mike.barger@kci1.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing